Pediatrix Medical Group (MD) Q1 2025 earnings summary

Executive summary

• Q1 2025 net revenue was $458.4 million, down 7.4% year-over-year, mainly due to practice dispositions, but same-unit revenue grew over 6% and NICU days increased 2%.

• Net income rose to $20.7 million from $4.0 million in Q1 2024, with Adjusted EBITDA up to $49.2 million from $37.2 million, driven by strong same-unit results and cost management.

• Strategic focus on hospital-based and maternal-fetal medicine services, with new contracts and completed exit from most office-based practices.

• Portfolio restructuring and practice optimization improved cost structure and margins.

• Management remains cautious due to ongoing healthcare sector and macroeconomic uncertainty.

Financial highlights

• Same-unit net revenue grew by $26.1 million (6.2%), with pricing up 4.6% year-over-year due to favorable payor mix and contract fees.

• Practice salaries and benefits decreased by $32.1 million (8.7%) due to practice dispositions.

• Operating margin improved to 7.0% from 3.2% year-over-year; Adjusted EBITDA margin also increased.

• Depreciation and amortization expense dropped to $5.3 million from $10.3 million, reflecting practice dispositions.

• Cash and cash equivalents were $99 million at March 31, 2025, down from $230 million at year-end 2024.

Outlook and guidance

• Full-year 2025 Adjusted EBITDA guidance raised to $220–$240 million, up from $215–$235 million, reflecting strong Q1 performance.

• Management expects funds from operations, cash, and credit to be sufficient for at least the next 12 months.

• The company anticipates continued compliance with all debt covenants throughout 2025.

• Management maintains a conservative outlook due to sector uncertainty and challenging comps for the rest of 2025.